Accelerated Enrollment Solutions (AES), a business unit of Pharmaceutical Product Development LLC (PPD), has acquired the clinical research site business of Bioclinica, expanding AES’ global footprint and solidifying its leardership position in patient access and site conduct. AES services now extend across five continents, 20 countries, over 180 research sites, and more than 100 million households, reports PPD in a recent press release.
What Countries does the Acquisition Help PPD Extend into?
New geographies include China, Latin America, and Western Europe, augmenting strong presence in North America, Europe and South Africa.
What Therapeutic Areas does this deal open up?
This adds therapeutic scope within the U.S., including dedicated research sites in Florida, branded Compass Research, with significant expertise in neuroscience.
The Transaction includes research sites from the merger of Bioclinica and CCBR-SYNARC in 2014. Who was this?
CCBR-SYNARC was a specialized clinical trials services vendor backed by private equity firms Water Street and Healthcare Partners.
AES, already a leading Site service, now gets stronger—how big are the aggregation of sites and patients?
PPD’s AES believes its offering to be the largest aggregation of fully identified, consented data on patients interested in participating in clinical trials.
What percent of the entire enrollment from one accountable solution can a Sponsor now achieve?
Roger Smith, SVP and GM of PPD’s AES reports that “With these new assets operating on five continents, AES is a place where customers can receive 50-100% of their entire trial enrollment from one accountable solution, delivered by research locations that operate uniformly across the globe.”
Accelerated Enrollment Solutions is a business unit of PPD that offers sponsors and contract research organizations best-in-class site conduct and patient access solutions. These solutions are available as discrete services or integrated to provide a cohesive and highly differentiated trial acceleration strategy for insourced or outsourced clinical studies, all under results-based commercial terms. For more information, visit here.
PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Their clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 48 countries and more than 21,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health. For more information, visit their website.
Bioclinica is a global life science provider that utilizes science and technology to bring clarity to clinical trials – helping companies to develop new life-improving therapies more efficiently and safely. For more information, visit here.